Fort Point Capital Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,181
| Closed | -$202K | – | 261 |
|
|
2026
Q1 | $202K | Buy |
+7,181
| New | +$191K | 0.02% | 222 |
|
|
2025
Q2 | – | Sell |
-12,608
| Closed | -$319K | – | 334 |
|
|
2025
Q1 | $319K | Buy |
+12,608
| New | +$330K | 0.04% | 262 |
|
|
2024
Q4 | – | Sell |
-12,184
| Closed | -$353K | – | 318 |
|
|
2024
Q3 | $353K | Buy |
12,184
+3,123
| +34% | +$91.1K | 0.04% | 221 |
|
|
2024
Q2 | $254K | Buy |
9,061
+434
| +5% | +$11.9K | 0.03% | 274 |
|
|
2024
Q1 | $239K | Buy |
+8,627
| New | +$239K | 0.03% | 286 |
|
|
2023
Q4 | – | Sell |
-9,955
| Closed | -$330K | – | 318 |
|
|
2023
Q3 | $330K | Hold |
9,955
| – | – | 0.05% | 196 |
|
|
2023
Q2 | $365K | Sell |
9,955
-554
| -5% | -$21.6K | 0.05% | 194 |
|
|
2023
Q1 | $429K | Sell |
10,509
-1,107
| -10% | -$47.8K | 0.07% | 178 |
|
|
2022
Q4 | $595K | Sell |
11,616
-2,000
| -15% | -$95.9K | 0.09% | 142 |
|
|
2022
Q3 | $596K | Buy |
13,616
+2,891
| +27% | +$140K | 0.1% | 139 |
|
|
2022
Q2 | $562K | Buy |
10,725
+162
| +2% | +$8.26K | 0.09% | 149 |
|
|
2022
Q1 | $547K | Buy |
10,563
+1,573
| +17% | +$81.6K | 0.08% | 163 |
|
|
2021
Q4 | $531K | Hold |
8,990
| – | – | 0.07% | 157 |
|
|
2021
Q3 | $387K | Sell |
8,990
-716
| -7% | -$31.7K | 0.06% | 166 |
|
|
2021
Q2 | $380K | Buy |
9,706
+250
| +3% | +$9.72K | 0.07% | 121 |
|
|
2021
Q1 | $343K | Buy |
+9,456
| New | +$336K | 0.07% | 118 |
|
|
2020
Q1 | – | Sell |
-5,852
| Closed | -$218K | – | 127 |
|
|
2019
Q4 | $218K | Sell |
5,852
-211
| -3% | -$7.52K | 0.08% | 119 |
|
|
2019
Q3 | $207K | Buy |
+6,063
| New | +$220K | 0.08% | 109 |
|
|
2019
Q1 | – | Sell |
-13,319
| Closed | -$552K | – | 141 |
|
|
2018
Q4 | $552K | Sell |
13,319
-50
| -0.4% | -$2.08K | 0.22% | 64 |
|
|
2018
Q3 | $559K | Buy |
13,369
+3,066
| +30% | +$118K | 0.17% | 75 |
|
|
2018
Q2 | $355K | Sell |
10,303
-3,770
| -27% | -$129K | 0.12% | 86 |
|
|
2018
Q1 | $474K | Buy |
14,073
+817
| +6% | +$28.1K | 0.17% | 81 |
|
|
2017
Q4 | $456K | Buy |
13,256
+6,503
| +96% | +$222K | 0.21% | 71 |
|
|
2017
Q3 | $229K | Buy |
+6,753
| New | +$217K | 0.11% | 112 |
|
|
2017
Q1 | – | Sell |
-6,862
| Closed | -$205K | – | 114 |
|
|
2016
Q4 | $205K | Sell |
6,862
-4,911
| -42% | -$150K | 0.11% | 99 |
|
|
2016
Q3 | $378K | Buy |
11,773
+432
| +4% | +$14.4K | 0.17% | 87 |
|
|
2016
Q2 | $379K | Buy |
11,341
+3,345
| +42% | +$107K | 0.18% | 78 |
|
|
2016
Q1 | $225K | Sell |
7,996
-1,894
| -19% | -$54.1K | 0.11% | 95 |
|
|
2015
Q4 | $303K | Buy |
+9,890
| New | +$311K | 0.15% | 83 |
|
Other funds holding PFE
Fort Point Capital Partners's PFE Position: Q2 2026 in Review
Fort Point Capital Partners sold out of Pfizer (PFE) in Q2 2026, closing a stake of 7,181 shares — an estimated $202K sold.
Fort Point Capital Partners first reported a position in PFE in Q4 2015 and held it in 29 quarters. The position peaked at $596K in Q3 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Fort Point Capital Partners reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
- Fort Point Capital Partners sold 7,181 Pfizer shares in Q2 2026, an estimated $202K.
- Fort Point Capital Partners first reported a position in Pfizer in Q4 2015 and held it in 29 quarters.
- Fort Point Capital Partners's Pfizer position peaked at $596K in Q3 2022.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Fort Point Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.